of patients with ALS at different degrees of disability, overcoming the current clinical follow-up deficit and giving patients a chance to recover interaction with environment. doi:10.1016/j.clinph.2018.09.066 Subcutaneous immunoglobulin (SCIG) for maintenance treat- ment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo- controlled trial: The PATH Study D. Cocito, E. Peci, G. Lauria Pinter, P. Dacci, A. Di Muzio, R. Telese, A. Schenone, L. Benedetti, G. Antonini, S. Morino, S. Sorbi, S. Matà, V. Bril, N. van Geloven, H.-P. Hartung, R.A. Lewis, G. Sobue, J.-P. Lawo, O. Mielke, B.L. Durn, D.R. Cornblath, I.S.J. Merkies, I.N. van Schaik, on behalf of the PATH study group Torino, Italy Milano, Italy Chieti, Italy Genova, Italy Roma, Italy Firenze, Italy Toronto, Italy DI ¨ sseldolf, Germany Los Angeles, USA Baltimore, USA Maastricht, Netherlands Amsterdam, Netherlands Several CIDP patients need long-term corticosteroids or intra- venous immunoglobulin (IVIG), with IVIG being associated with improved safety profile. SCIG is an alternative option for immunoglobulin delivery but it was not investigated in large-scale trials in CIDP. PATH was a randomized, double-blind trial investigat- ing 0.2 and 0.4 g/kg weekly doses of SCIG IgPro20 (Hizentra Ò , CSL Behring) versus placebo for maintenance treatment in 172 CIDP patients. IVIG-dependent adults with definite or probable CIDP were eligible. The primary outcome was the percentage of subjects with a CIDP relapse (1-point deterioration on adjusted INCAT disability score) or who were withdrawn for any reason during the 24-week SCIg-treatment. Multiple secondary endpoints were assessed. Overall, 33% of patients on high-dose SCIG, 39% of those on low- dose SCIG and 63% of placebo recipients experienced CIDP relapse or were withdrawn from treatment (p < 0.05 for both SCIG doses vs placebo). INCAT score, MRC sum score, and grip strength remained stable with SCIG, while they deteriorated with placebo. High-dose SCIG prevented R-ODS decline. Adverse events occurred in 47 (27%) patients (18% placebo, 30% low-dose, and 35% high- dose). Both IgPro20 doses were effective and safe as maintenance treatment in patients with CIDP, compared with placebo. doi:10.1016/j.clinph.2018.09.067 Rhabdomyolysis and acute neuromyopathy associated with the combined use of statin and colchicine: A case report and a review of the literature D. Liuzzi, G. Masi, C. Dell’Aquila, G. Palagano, L.P. Cotogni, G. Rinaldi Bari, Italy To report a case of colchicine-induced rhabdomyolysis and neu- romyopathy in a patient treated with atorvastatin and colchicine and to review the literature about this topic. A 69-year-old man affected by diabetes mellitus and chronic renal insufficiency was prescribed atorvastatin, after that an ischemic stroke occurred, with no side effect. After 2 months colchicine (0.5 mg three times a day) was added to treat pericarditis and six weeks later, the patient began to experience increasing symmetrical proximal muscle weakness which was worse in the legs. Laboratory results suggested rhab- domyolysis, while physical examination and electromyography find- ings were consistent with neuromyopathy. One month after the discontinuation of colchicine and atorvastatin, the patient weakness improved and muscle enzymes levels returned to normal levels. Eleven patients with clinical and laboratory characteristics similar to our patient’s caused by the combined use of colchicine and statins have been previously described in literature. Both colchicine and sta- tin therapy may be associated with myopathy. Co-administration may exacerbate the myotoxicity because both drugs metabolism depend on hepatic demethylation through CYP450 3A4. Combination therapy with colchicine and statin should be avoided because of the risk of developing myopathy and rhabdomyolysis even after a long uneventful statin or colchicine medication. doi:10.1016/j.clinph.2018.09.068 Heteronymous h temporal reflex as sign of hyperexcitability in ALS T. Barone, L. Libonati, G. Fanella, V. Pozzilli, I. Fiorini, S. Di Bari, M. Goglia, M. Romano, E. Masini, G. Tartaglia, C. Cambieri, M. Ceccanti, E. Onesti, V. Frasca, M. Inghilleri Roma, Italy The stimulation of masseteric nerve elicits an H reflex (Hr) both in the masseter muscle and in the temporalis muscle. The heterony- mous Hr can be used to assess the excitability of a-MN and it can be considered a sign of upper motor neuron involvement in ALS patients. The aim of this study is to analyze the presence of this reflex in ALS patients and in normal subjects. We enrolled 29 ALS patients and 38 normal subjects. We recorded the Hr and M-wave from masseter and temporalis muscle response, by the stimulation of the masseteric nerve. We found a statistically significant differ- ence in the excitability of heteronymous H reflex which was more elicitable in ALS patients than in healthy people of the same age. Brisk jerk is considered a sign of a-MN hyperexcitability in corti- cospinal tract damage. In ALS patients, damage of the corticospinal tract produces an enhanced Hr that it is more easily recorded than in normal subjects. doi:10.1016/j.clinph.2018.09.069 Electrophysiological assessment of lower cranial nerve palsy triggered by spontaneous extracranial carotid dissection G. Salomone, S. Ricci, F. Rossi, M. Turazzini, V. Annese, R. Del Colle, A. Polo Legnago, Italy A 43-year-old man was admitted to our department for the acute onset of unilateral right throbbing headache. Neurologic examina- tion revealed right ocular myosis and ptosis, left displacement of the uvula, dysphonia, weak left-turning of the head, right scapular winging on arm abduction and right tongue deviation, suggesting 9th through 12th cranial nerve palsy and Horner’s syndrome. Neurophysiologic examination confirmed the unilateral involve- ment. EMG showed loss of motor unit recruitment and denervation activity in the right sternocleidomastoid, trapezius and genioglossus muscles. MEPs and C-MAP were not excitable from those muscles. MRI demonstrated a crescent-shaped hyperintense T1 and T2 signal within the wall of the distal extracranial portion of the right internal carotid artery (ICA), suggesting an intramural hematoma causing e10 Abstracts / Clinical Neurophysiology 130 (2018) e1–e19